Evidence map›Paper›PMID 27803608›Full record

ArticleCurrent oncology (Toronto, Ont.)2016

Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma.

A Salman, E Simoneau, M Hassanain, P Chaudhury, L M Boucher, D Valenti, T Cabrera, C Nudo, P Metrakos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Radioembolization in the Setting of Systemic Therapies.Seminars in interventional radiology · 2021
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Signature of survival: aOncotarget · 2018
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

A SalmanDepartment of Surgery, Division of Hepatopancreatobiliary and Transplant Surgery, McGill University, Montreal, QC.
E SimoneauDepartment of Surgery, Division of Hepatopancreatobiliary and Transplant Surgery, McGill University, Montreal, QC.
M HassanainDepartment of Oncology, McGill University, Montreal, QC; Department of Surgery, King Saud University, Riyadh, Saudi Arabia.
P ChaudhuryDepartment of Surgery, Division of Hepatopancreatobiliary and Transplant Surgery, McGill University, Montreal, QC; Department of Oncology, McGill University, Montreal, QC.
L M BoucherDepartment of Radiology, Division of Interventional Radiology, McGill University, Montreal, QC.
D ValentiDepartment of Radiology, Division of Interventional Radiology, McGill University, Montreal, QC.
T CabreraDepartment of Radiology, Division of Interventional Radiology, McGill University, Montreal, QC.
C NudoDepartment of Medicine, Division of Hepatology, McGill University, Montreal, QC.
P MetrakosDepartment of Surgery, Division of Hepatopancreatobiliary and Transplant Surgery, McGill University, Montreal, QC; Department of Oncology, McGill University, Montreal, QC.
McGill University · CAMcGill University Health Centre · CAKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsIn this pilot study, we assessed the safety and tolerability of combining sorafenib with

methodsThe study, conducted prospectively during 2009-2012, included eligible patients with unresectable hcc and a life expectancy of at least 12 weeks. Each patient received sorafenib (400 mg twice daily) for 6-8 weeks before

resultsOf the 40 patients enrolled, 29 completed treatment (combined therapy). In the initial cohort, the most common cause of hcc was hepatitis C (32.5%), and most patients were staged Child A (82.5%). The 29 patients who completed the study had similar baseline characteristics. Grades 1 and 2 toxicities accounted for 77.8% of all adverse events reported. The most common toxicities reported were fatigue (19.0%), alteration in liver function (7.9%), and diarrhea (6.3%). There were 12 grade 3 and 2 grade 4 toxicity events reported. One patient died of liver failure within 30 days after treatment. During the study, the sorafenib dose was reduced in 6 patients (20.7%), and sorafenib had to be interrupted in 4 patients (13.8%) and discontinued in 4 patients (13.8%). The disease control rate was 72.4% per the modified Response Evaluation Criteria in Solid Tumors, and tumour necrosis was observed in 82.8% of patients. Overall survival in patients undergoing combined therapy was 12.4 months.

conclusionsPreliminary results demonstrate the safety and tolerability of combining

Indexed as

Hepatocellular carcinomaradioembolizationsorafenibunresectability

Identifiers

PMID27803608
PMCPMC5081020
OpenAlexW2546188472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.